Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

AL Amyloidosis Therapy and Targets in 2019: Bortezomib Remains Mainstay in Frontline, ASCT in Upfront Is Questionable, Targeted Therapies Offer Promise, IO to Be Proven

88 views
November 18, 2019
Comments 0
Login to view comments. Click here to Login